- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04509284
Analgesic Effect of Resistance Training for Breast Cancer Survivors ((ANTRAC))
Effect of Resistance Training of Persistent Pain After Breast Cancer
Persistent pain after treatment for breast cancer is a major clinical problem, affecting 25-60 % of the patients and is a source of considerable physical disability and psychological distress. Thus, the development of novel interventions to improve pain management for these patients is of clinical importance. Resistance training (RT) is a promising tool to combat a variety of undesirable adverse effects due to breast cancer treatment. Further, research suggests that it may also be able to provide pain-relieving benefits.
Hypothesis: Resistance training will improve pain perception and physical function in the short- and long term compared to a non-training control group.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Northern Jutland
-
Aalborg, Northern Jutland, Denmark, 9220
- Department of Health Science and Technology, Aalborg University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- primary diagnosis of breast cancer (grades I-IIIA).
- adult women at least 18 years of age.
- having received breast cancer treatment (i.e. surgery and possible adjuvant chemo and/or radiotherapy) at least 18 months before the start of the study.
- self reported pain in the areas of the breast, shoulder, axilla, arm and/or side of body with an intensity of ≥ 3 on a numeric rating scale (0 = no pain, 10 = worst pain imaginable).
- no signs of cancer recurrence.
- reading, writing and speaking Danish.
Exclusion Criteria:
- breast surgery for cosmetic reasons or prophylactic mastectomy.
- bilateral breast cancer.
- lymphedema.
- other chronic pain conditions (e.g., rheumatoid arthritis).
- previous diagnosis of fibromyalgia syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Training
Participants with persistent pain after breast cancer treatment will receive 24 sessions of individualized progressive total body resistance training, supervised by a certified strength and conditioning specialist.
|
The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period.
The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions.
Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed.
A 3-5min rest period is provided throughout the program.
|
|
Other: Control
Participants with persistent pain after breast cancer treatment will be instructed to continue their everyday lifestyle and be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
|
The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet.
However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in pain sensitivity, assessed through pressure pain thresholds.
Time Frame: Baseline and at 3, and 6 months
|
Between group comparisons of treatment effect (change in pressure pain thresholds) from baseline to follow-up) will be performed.
Pressure pain thresholds will be collected with a pressure algometer with a progressive increment in pressure of 30kPa.
|
Baseline and at 3, and 6 months
|
|
Change in pain intensity, assessed through a 11 point numeric rating scale (0 = no pain, 10 = worst pain imaginable).
Time Frame: Baseline and at 3, and 6 months
|
Pain intensity is collected in two different contexts; 1) recollection for the past 3 months and 2) movement evoked pain during testing and training.
|
Baseline and at 3, and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscular strength assesses through a 1 repetition maximum (1RM)
Time Frame: Baseline and at 3, and 6 months
|
1RM box squat, bench press, trapbar deadlift, bench pull and lat pulldown conducted in accordance with the recommendations of the American College of Sports Medicine (ACSM)
|
Baseline and at 3, and 6 months
|
|
Active shoulder range of motion assessed with a universal goniometer.
Time Frame: Baseline and at 3, and 6 months
|
Active range of motion for the affected shoulder is collected for shoulder flexion, horizontal shoulder flexion/extension, shoulder abduction and internal/external shoulder/rotation
|
Baseline and at 3, and 6 months
|
|
Body composition assessed through bioelectrical impedance measurements.
Time Frame: Baseline and at 3, and 6 months
|
Estimates of body fat mass, fat free mass, skeletal muscle mass and bodyfat percentage are collected from bioelectrical impedance using an InBody370 device.
|
Baseline and at 3, and 6 months
|
|
Arm circumference measured bilaterally at a single point 30cm above the styloid process.
Time Frame: Baseline and at 3, and 6 months
|
Arm circumference is collected to assess potential lymphedema development.
A difference in circumference of >10% between arms is considered indicative of lymphedema.
|
Baseline and at 3, and 6 months
|
|
Physical activity level assessed through the international physical activity questionnaire (IPAQ).
Time Frame: Baseline and at 3, and 6 months
|
IPAQ estimates physical activity level as "low", "moderate" or "high" from the number of days and time per day conducting either hard, moderate or easy physical activity for the pas seven days.
|
Baseline and at 3, and 6 months
|
|
Health related quality of life assessed through the European Organisation for Research and Treatment of Cancer (EORCT)-C30 quality of life questionaire
Time Frame: Baseline and at 3, and 6 months
|
The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.
|
Baseline and at 3, and 6 months
|
|
Quality of life assessed through the breast cancer specific European Organisation for Research and Treatment of Cancer (EORCT)-BR23 quality of life questionaire
Time Frame: Baseline and at 3, and 6 months
|
The EORCT-C30 QLQ estimates quality of life through a series of questions regarding the extent to which the respondee experience various restrictions in physical function and well-being common in breast cancer patients, ranging from 1 (not at all) to 4 (A lot) on a four point likert scale.
|
Baseline and at 3, and 6 months
|
|
Cancer fatigue assessed through the Functional Assessment of Chronic Illness Therapy (FACIT) - fatigue scale.
Time Frame: Baseline and at 3, and 6 months
|
The FACIT-scale estimates fatigue through a series of questions regarding the extent to which the respondee experience various symptoms of fatigue, ranging from 0 (not at all) to 4 (A lot) on a five point likert scale.
|
Baseline and at 3, and 6 months
|
|
Mental health assessed through the Major Depression Index (MDI)
Time Frame: Baseline and at 3, and 6 months
|
The MDI estimates mental health through a series of questions regarding the extent to which the respondee experience various symptoms of depression, ranging from 0 (never) to 5 (All the time) on a five point likert scale.
|
Baseline and at 3, and 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Summative process evaluation
Time Frame: At 3 months
|
The summative process evaluation include the following: 1) Context of the intervention described qualitatively, 2) the dose delivered as %'age of the planed sessions effectively implemented, 3) dose received as %'age of planned sessions effectively received, 4) fidelity measured through the following items: (1) whether the training groups (i.e.
same participants every session) during training sessions were consistent; (2) whether the instructors delivered all their sessions as initially scheduled; (3) whether warm-up and training were offered in accordance with the time schedules initially planned; (4) whether the time schedule were respected by participants and instructors and 5) satisfaction, rated as level of agreement with a series of statements on a five-point likert scale 1=strongly disagree, 2=disagree, 3=uncertain, 4=agree, and 5=strongly agree.
|
At 3 months
|
|
Training log, collecting daily readiness for exertion, performance, perceived exertion level and movement evoked pain.
Time Frame: Every session for 12 weeks.
|
Daily readiness for exertion is assessed at two levels (mental and physical) prior to the warm up and each exercise on a 0-11 numeric rating scale (0 = no readiness, 10 = maximum readiness.
Performance i collected as setsXrepsXload per exercise per session.
Perceived level of exertion is assessed through a resistance training specific Rating of Perceived Exertion (RPE) scale based on repetitions in reserve.
Movement-evoked pain is assessed per set for each exercise on a 11 point numeric rating scale (0= no pain, 10 = maximum pain).
|
Every session for 12 weeks.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Pascal Madeleine, Dr. Scient, Aalborg University
- Study Chair: Michael Voigt, Ph. D., Aalborg University
- Study Chair: Mathias Kristiansen, Ph. D., Aalborg University
- Study Chair: Manuel Arroyo-Morales, Dr. Med, Universidad de Granada
Publications and helpful links
General Publications
- Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003 Jul;104(1-2):1-13. doi: 10.1016/s0304-3959(03)00241-0. No abstract available.
- Cronin-Fenton DP, Norgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, Sorensen HT. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer. 2007 May 7;96(9):1462-8. doi: 10.1038/sj.bjc.6603717. Epub 2007 Apr 3.
- De Backer IC, Schep G, Backx FJ, Vreugdenhil G, Kuipers H. Resistance training in cancer survivors: a systematic review. Int J Sports Med. 2009 Oct;30(10):703-12. doi: 10.1055/s-0029-1225330. Epub 2009 Jul 7.
- Rice D, Nijs J, Kosek E, Wideman T, Hasenbring MI, Koltyn K, Graven-Nielsen T, Polli A. Exercise-Induced Hypoalgesia in Pain-Free and Chronic Pain Populations: State of the Art and Future Directions. J Pain. 2019 Nov;20(11):1249-1266. doi: 10.1016/j.jpain.2019.03.005. Epub 2019 Mar 21.
- Rasmussen GHF, Madeleine P, Arroyo-Morales M, Voigt M, Kristiansen M. Resistance Training-Induced Acute Hypoalgesia in Women With Persistent Pain After Breast Cancer Treatment. J Strength Cond Res. 2022 Sep 28. doi: 10.1519/JSC.0000000000004320. Online ahead of print.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N-20180090
- R204-A12469 (Other Grant/Funding Number: Danish Cancer Society)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Training
-
Northeastern UniversityOregon Health and Science University; University of California, RiversideRecruiting
-
University of Trás-os-Montes and Alto DouroCompletedLipid Metabolism Disorders | Sarcopenia | Osteoporosis | Overweight and Obesity | Personal Satisfaction | Hypertension With Complications and Secondary HypertensionPortugal
-
New Jersey Institute of TechnologyRutgers, The State University of New JerseyCompletedHemiplegia | Hemiparesis | Cerebrovascular AccidentUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompletedHypertension | Diabetes | Peripheral Arterial DiseaseBrazil
-
Recep Tayyip Erdogan UniversityThe Scientific and Technological Research Council of TurkeyCompletedAthletic PerformanceTurkey (Türkiye)
-
Foundation for Atlanta Veterans Education and Research...United States Department of Defense; NYU Langone Health; University of Rochester and other collaboratorsRecruitingStress Disorders, Post-TraumaticUnited States
-
Lebanese UniversityCompletedHeart Failure | Quality of Life | Cardiac Rehabilitation | Aerobic Exercise | Exercise Intolerance | Respiratory Muscle Training | Strength Training
-
Poznan University of Physical EducationPoznan University of Medical Sciences; National Science Centre, PolandActive, not recruitingHealthy Athletes Aged 18-35 YearsPoland